Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Alderuccio, Juan Pablo, Desai, Amrita, Yepes, Monica M., Chapman, Jennifer R., Vega, Francisco, Lossos, Izidore S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://www.ncbi.nlm.nih.gov/pubmed/29636930
http://dx.doi.org/10.1002/ccr3.1382
_version_ 1783312670831673344
author Alderuccio, Juan Pablo
Desai, Amrita
Yepes, Monica M.
Chapman, Jennifer R.
Vega, Francisco
Lossos, Izidore S.
author_facet Alderuccio, Juan Pablo
Desai, Amrita
Yepes, Monica M.
Chapman, Jennifer R.
Vega, Francisco
Lossos, Izidore S.
author_sort Alderuccio, Juan Pablo
collection PubMed
description We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.
format Online
Article
Text
id pubmed-5889253
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58892532018-04-10 Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma Alderuccio, Juan Pablo Desai, Amrita Yepes, Monica M. Chapman, Jennifer R. Vega, Francisco Lossos, Izidore S. Clin Case Rep Case Reports We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL. John Wiley and Sons Inc. 2018-02-16 /pmc/articles/PMC5889253/ /pubmed/29636930 http://dx.doi.org/10.1002/ccr3.1382 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Alderuccio, Juan Pablo
Desai, Amrita
Yepes, Monica M.
Chapman, Jennifer R.
Vega, Francisco
Lossos, Izidore S.
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title_full Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title_fullStr Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title_full_unstemmed Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title_short Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
title_sort frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889253/
https://www.ncbi.nlm.nih.gov/pubmed/29636930
http://dx.doi.org/10.1002/ccr3.1382
work_keys_str_mv AT alderucciojuanpablo frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma
AT desaiamrita frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma
AT yepesmonicam frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma
AT chapmanjenniferr frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma
AT vegafrancisco frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma
AT lossosizidores frontlinebrentuximabvedotininbreastimplantassociatedanaplasticlargecelllymphoma

Ejemplares similares